YOLFTbeta
Greenwich Lifesciences Inc

Greenwich Lifesciences Inc

GLSI · NASDAQ · Healthcare / Biotechnology

14.94USD-0.34 (-2.23%)

Price History

Full chart

Market Stats

Previous Close15.28
Open15.87
Day Range14.56 – 15.87
52-Week Range7.78 – 34.10
Volume73.71K
Market Cap265.68M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.65
Dividend Yield0.00%
Beta1.46
50-Day Avg15.86
200-Day Avg21.67

About

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Snehal S. Patel
  • Employees4
  • HeadquartersBuilding 14, Stafford, TX, United States, 77477, USA
  • Websitehttps://greenwichlifesciences.com

Leadership

  • Mr. Snehal S. PatelCEO, CFO & Director · b. 1964
  • Mr. Eric RotheFounder & Independent Director · b. 1975
  • Dr. Frank Joseph Daugherty M.D.Chief Medical Officer & Director · b. 1951
  • Dr. Jaye L. Thompson Ph.D.Vice President Clinical & Regulatory Affairs · b. 1966
  • Dr. Christine T. Fischette Ph.D.VP of Business Development · b. 1951

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-00000000
Cost of Revenue3.61K3.61K3.61K3.61K3.61K3.61K3.61K3.61K1.78K
Gross Profit-3.61K-3.61K-3.61K-3.61K-3.61K-3.61K-3.61K-3.61K-1.78K
Operating Expense1.57M1.69M3.42M1.86M4.59M8.04M9.32M17.63M19.45M
Operating Income-1.57M-1.69M-3.43M-1.86M-4.60M-8.04M-9.33M-17.64M-19.45M
EBITDA-1.57M-1.69M-3.42M-1.86M-4.57M-7.82M-8.89M-17.41M-19.36M
Net Income-1.57M-1.69M-3.43M-1.86M-4.57M-7.83M-8.89M-17.41M-19.36M
R&D1.22M1.27M2.61M1.06M3.56M6.48M7.70M15.48M17.22M
Interest Expense-00027.37K215.02K---

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets27.10K108.55K26.67K28.68M27.22M13.48M6.99M4.09M6.18M
Total Liabilities8.56M10.23M1.38M1.05M385.17K262.90K294.41K3.19M5.82M
Total Equity-8.53M-10.12M-1.35M27.63M26.83M13.21M6.70M908.63K353.22K
Cash5485.10K6.83K28.66M27.20M13.47M6.99M4.09M6.18M
Total Debt-420.15K635.15K275.15K-----
Net Debt-54-85.10K628.32K-28.39M-27.20M-13.47M-6.99M-4.09M-6.18M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-120.85K-114.95K-293.27K-1.15M-4.29M-6.20M-6.48M-7.27M-9.91M
Financing Cash Flow-129.84K200.00K215.00K29.81M2.84M-7.54M04.37M12.00M
Capital Expenditure000003033
Free Cash Flow-120.85K-114.95K-293.27K-1.15M-4.29M-6.20M-6.48M-7.27M-9.91M
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateMar 31, 2019Jun 30, 2019Sep 30, 2019Jan 28, 2020Jun 23, 2020Sep 28, 2020Nov 16, 2020Mar 31, 2021May 20, 2021Aug 13, 2021Nov 15, 2021Mar 21, 2022May 20, 2022Aug 15, 2022Nov 14, 2022Mar 1, 2023May 22, 2023Aug 21, 2023Oct 19, 2023Mar 31, 2024May 20, 2024Aug 14, 2024Nov 14, 2024Feb 26, 2025May 20, 2025Aug 14, 2025Nov 14, 2025Feb 25, 2026May 26, 2026Aug 11, 2026Nov 13, 2026
EPS Estimate0.000.000.000.000.000.00-0.03-0.93-0.32-0.32-0.06-0.07-0.19-0.19-0.19-0.22-0.23-0.23-0.22-0.22-0.20-0.20-0.21-0.21-0.24-0.24-0.36-0.34-0.32-0.33-0.34
EPS Actual-0.73-12.83-1.15-0.27-0.02-0.02-0.03-0.12-0.05-0.06-0.07-0.18-0.15-0.06-0.18-0.22-0.17-0.13-0.19-0.21-0.19-0.20-0.20-0.61-0.25-0.30-0.30-0.58-0.39-0.27-
Surprise------0.00%87.10%84.38%81.25%-16.67%-157.14%21.05%68.42%5.26%0.00%26.09%43.48%13.64%2.82%5.00%0.00%4.76%-190.48%-4.17%-25.00%16.67%-70.59%-21.88%18.18%-
Timing-----After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap265.68M
Enterprise Value246.67M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book81.99
EPS-1.65
Book Value0.212
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-22.66M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-986.32%
Return on Assets-235.98%
Shares Outstanding14.68M
Shares Float7.65M
Beta1.46
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 57.00
  • Buy
    1

Ownership Breakdown

Institutions
12.25%
Insiders
47.91%
Retail / Other
39.84%

Top Institutional Holders

  • BlackRock Inc
    433.86K2.96%
  • Vanguard Capital Management, LLC
    298.27K2.03%
  • Geode Capital Management, LLC
    155.47K1.06%
  • State Street Corp
    133.88K0.91%
  • Nuveen, LLC
    88.72K0.60%
  • Northern Trust Corp
    75.13K0.51%
  • Vanguard Portfolio Management, LLC
    58.91K0.40%
  • Bank of New York Mellon Corp
    46.52K0.32%
  • Vanguard Fiduciary Trust Co
    44.91K0.31%
  • The Goldman Sachs Group Inc
    39.52K0.27%
  • Ancora Advisors LLC
    37.50K0.26%
  • Morgan Stanley - Brokerage Accounts
    29.83K0.20%
  • SEI Investments Co
    26.09K0.18%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    199.01K1.36%
  • iShares Russell 2000 ETF
    177.94K1.21%
  • Fidelity Small Cap Index
    73.67K0.50%
  • iShares Russell 2000 Growth ETF
    63.76K0.43%
  • Vanguard Russell 2000 ETF
    38.63K0.26%
  • Vanguard US Momentum Factor ETF
    34.27K0.23%
  • Fidelity Extended Market Index
    30.20K0.21%